Funded Tech Companies

Arcus Biosciences

Researching who invested in Arcus Biosciences? Taiho Ventures, GV and Celgene put venture money into this biopharmaceutical company.

Company Overview

Contact Information

Company Background Information

Overview

Arcus Biosciences (NYSE: RCUS) The field of immuno-oncology (or cancer immunotherapy) has exploded in the past decade. Cancer immunotherapies generally work by interfering with the inhibitory signals produced by tumors against certain elements of the immune system. Arcus is initially developing drug therapies for small molecules along the ATP-adenosine pathway.

Profile

Social Media

Company News

Facebook

YouTube

Last Transaction

3/15/2018

Financing History

Management Team

Title

Name

Email & Social

Chief Executive Officer

Terry Rosen

        

President

Juan Jaen

        

Vice President

Andrew Pennell

        

Vice President

Jay Powers

        

Vice President

Ulrike Schindler

        

Vice President

Nigel Walker

        

VP - Bus. Development

Timothy Sullivan

        

VP - Engineering

Steve Young

        

Company Investors

• Taiho Ventures
• GV
• Celgene
• Invus
• Leerink Partners
• BVF Partners
• The Column Group
• Hillhouse Capital Group
• Wellington Management Company
• Aisling Capital
• Foresite Capital
• DROIA
• EcoR1 Capital Management
• Decheng Capital
• Novartis Venture Fund

Browse more funded tech companies:

Arcturus Therapeutics | Arcxis Biotechnologies

Share this article

About Our VC Deals Database

This tech company profile is powered by VentureDeal.com, a leading provider of venture capital transaction data.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary